Teichos Laboratories, LLC. (Teichos) is described as a business-to-business biotechnology company employing chemoenzymatic synthesis to access its platform of macromolecular biologics for diverse applications in immunotherapy and vaccine development. The firm is elsewhere discussed as developing a platform technology based upon critical cellular structural and signaling molecules of organisms found in all terrestrial microbiomes iwith the objective being improved animal health vaccine effectiveness. Teichos adjuvants can improve the performance of virtually any under-performing vaccine, producing increased feed efficiency, animal health and welfare, food safety, and reduced environmental concern
